Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib by Lynch Thomas J, Bell Daphne W, Sordella Raffaella, Gurubhagavatula Sarada, Okimoto Ross A, Brannigan Brian W, Harris Patricia L, Haserlat Sara M, Supko Jeffrey G, Haluska Frank G, Louis David N, Christiani David C, Settleman Jeff, Haber Daniel A in The New England journal of medicine (2004).

[PMID: 15118073] PubMed


Most patients with non-small-cell lung cancer have no response to the tyrosine kinase inhibitor gefitinib, which targets the epidermal growth factor receptor (EGFR). However, about 10 percent of patients have a rapid and often dramatic clinical response. The molecular mechanisms underlying sensitivity to gefitinib are unknown.

[ hide abstract ]

Discussed In Paper


Variant Annotations

Sign in to see variant annotations.

Rx Annotations

No dosing information annotated.